# Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes

> **NCT06891157** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 148 (estimated)

## Conditions studied

- Chidamide
- R-CHOP Chemotherapy
- DLBCL - Diffuse Large B Cell Lymphoma
- Double-expressor Lymphoma (DEL)

## Interventions

- **DRUG:** Chidamide plus R-CHOP

## Key facts

- **NCT ID:** NCT06891157
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-20
- **Primary completion:** 2027-08-20
- **Final completion:** 2027-08-20
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06891157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06891157, "Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06891157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*